‼️ 💊 BREAKING: Merck beat quarterly estimates and raised its adjusted EPS outlook to $2.77–$2.82 from $2.66–$2.76, including a $400 million, or 12-cent-per-share, charge tied to its SciBrunch licensing deal. The company is banking on Keytruda Qlex, a more convenient under-the-skin injection, to drive growth by transitioning patients from the original intravenous treatment.
